Kramer Kelly A. 4
4 · GILEAD SCIENCES, INC. · Filed Dec 1, 2025
Insider Transaction Report
Form 4
Kramer Kelly A.
Director
Transactions
- Exercise/Conversion
Common Stock
2025-11-26$81.00/sh+2,806$227,286→ 4,145 total - Sale
Common Stock
2025-11-26$127.11/sh−2,806$356,671→ 1,339 total - Exercise/Conversion
Common Stock
2025-11-28$81.00/sh+2,805$227,205→ 4,144 total - Sale
Common Stock
2025-11-28$127.10/sh−2,805$356,516→ 1,339 total - Exercise/Conversion
Non-qualified Stock Option (Right to Buy)
2025-11-26−2,806→ 2,805 totalExercise: $81.00Exp: 2026-08-19→ Common Stock (2,806 underlying) - Exercise/Conversion
Non-qualified Stock Option (Right to Buy)
2025-11-28−2,805→ 0 totalExercise: $81.00Exp: 2026-08-19→ Common Stock (2,805 underlying)
Footnotes (2)
- [F1]The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 27, 2025.
- [F2]Options vest quarterly over the first year of service and were fully vested on August 19, 2017.